Gene therapy for pompe disease effective in mice, poised for human trials

January 26, 2017

After decades investigating a rare, life-threatening condition that cripples the muscles, Duke Health researchers have developed a gene therapy they hope could enhance or even replace the only FDA-approved treatment currently available to patients.

The gene therapy, demonstrated in mice, is described in a new study published online in the journal Molecular Therapy - Methods & Clinical Development. The therapy uses a modified virus to deliver a gene to the liver where it produces GAA, an enzyme missing in people with Pompe disease.

Study authors have received approval from the FDA to launch a Phase 1 clinical trial in humans and are currently working to secure funding.

Pompe disease is an inherited condition that affects approximately 1 in 20,000 babies and can also appear in adulthood. People with the condition lack the enzyme GAA, which means their bodies can't metabolize the sugar, glycogen. As a result, glycogen builds up in the muscles. In babies, this leads to improper muscle development and, if undiagnosed and untreated, can lead to respiratory problems, heart failure and death.

"The outlook for Pompe disease is much improved since enzyme replacement has become available—it can reverse involvement of the heart and prolong survival," said senior author Dwight Koeberl, M.D., Ph.D., professor of pediatrics and a medical genetics specialist at Duke.

"But not everyone responds to this treatment," Koeberl said. "Many patients make some antibodies, and this can really interfere with treatment. Some infants still die from Pompe disease. Others have to add immune suppression to their treatment, which can lead to other complications. Gene therapy could help these patients."

The Duke-led research team found that a single small dose of gene therapy was as effective as (ERT) in clearing the buildup of glycogen from the muscles in mice. A larger dose offered superior results to ERT. A single treatment spurred the liver to continuously produce GAA without additional treatment, the study authors said. Enzyme therapy requires infusions once or twice a month to lower glycogen levels in the muscles.

The video will load shortly.
Dwight Koeberl, M.D., Ph.D., describes a new gene therapy for Pompe disease Duke Health has developed and tested in mice. Researchers have FDA approval to launch a Phase 1 human trial and are working to secure funding. Credit: Shawn Rocco/ Duke Health

Unlike ERT, the gene therapy doesn't trigger an , a reaction that can limit successful treatment in about half of babies with Pompe. In fact, the gene therapy appeared to reverse immune responses in mice that had previously developed antibodies in response to enzyme replacement, Koeberl said.

The gene therapy uses an inactivated form of adeno-associated virus (AAV), which does not cause illness and has been used as a delivery system for hemophilia B and muscular dystrophy treatments, among others, Koeberl said.

The emerging is just the latest development for a team of scientists at Duke that has been working for three decades to study the causes and potential treatments for glycogen-storage diseases and specifically Pompe.

"When we enter our careers in the field of genetics, we are faced with the many unmet needs for patients with rare diseases," said Priya Kishnani, M.D., chief of the medical genetics division at the Duke University School of Medicine. "Before enzyme replacement became available in 2006 for Pompe disease, we would continue to give parents bad news—take your beautiful baby home; he or she will die within their first year of life. I knew we had to do something about this."

Kishnani has researched Pompe for 25 years, beginning under prominent geneticist Y.T. Chen, the previous chief of the medical genetics division at Duke. In the 1990s and 2000s, Chen and Kishnani worked with biotech firm Genzyme to develop ERT and lead clinical trials.

Since then, Kishnani and dozens of other Duke physicians have been national leaders in Pompe disease, continuing to research the condition, improve the delivery of ERT, manage immune responses to the drug and improve genetic counseling for families.

The Duke team has helped develop a blood test to diagnose Pompe and a biomarker to monitor severity of the disease and patients' response to treatment. For nearly 10 years, Kishnani has led a group of physicians to advocate nationally for universal newborn screening, which became a formal recommendation of the U.S. Department of Health and Human Services in 2015. The team's next step is to develop small molecule or oral drugs that could suppress the buildup of glycogen in the muscles.

"There's a rich heritage of expertise on glycogen storage disease at Duke, spanning about 40 years," Kishnani said. "We have continued to grow from the era of cloning the genes to developing animal models, to collaborating with pharma to conduct clinical trials here at Duke. I think we have come full circle, from bench to bedside and back to the bench in every aspect of the disease."

Explore further: Study identifies potential new avenue for treating pompe disease

More information: Sang-oh Han et al, Low-dose liver targeted gene therapy for Pompe disease enhances therapeutic efficacy of ERT via immune tolerance induction, Molecular Therapy - Methods & Clinical Development (2017). DOI: 10.1016/j.omtm.2016.12.010

Related Stories

Study identifies potential new avenue for treating pompe disease

July 27, 2016
Researchers at Duke Health have identified a potential new avenue for treating Pompe disease, a rare condition caused by the build-up of glycogen, a storage form of sugar, in cardiac and skeletal muscle, the liver and other ...

Targeted gene therapy enhances treatment for Pompe disease

June 25, 2012
Gene therapy to replace the protein missing in Pompe disease can be effective if the patient's immune system does not react against the therapy. Targeted delivery of the gene to the liver, instead of throughout the body,suppresses ...

Cancer drugs help the hardest cases of Pompe disease

January 5, 2012
Kids with Pompe disease fail because of a missing enzyme, GAA, that leads to dangerous sugar build-up, which affects muscles and movement. An enzyme replacement treatment pioneered at Duke University has saved many lives, ...

Anti-cancer drug fights immune reaction in some infants with Pompe disease

October 11, 2012
Adding a third anti-cancer agent to a current drug cocktail appears to have contributed to dramatic improvement in three infants with the most severe form of Pompe disease—a rare, often-fatal genetic disorder characterized ...

Research yields potential treatment approach for glycogen storage disease

November 18, 2015
Researchers from the Duke-NUS Graduate Medical School Singapore (Duke-NUS) and Duke Medicine have identified a potential treatment strategy for an often-fatal inherited glycogen storage disease.

Recommended for you

Scientists identify key regulator of male fertility

September 19, 2017
When it comes to male reproductive fertility, timing is everything. Now scientists are finding new details on how disruption of this timing may contribute to male infertility or congenital illness.

A piece of the puzzle: Eight autism-related mutations in one gene

September 19, 2017
Scientists have identified a hotspot for autism-related mutations in a single gene.

New assay leads to step toward gene therapy for deaf patients

September 18, 2017
Scientists at Oregon State University have taken an important step toward gene therapy for deaf patients by developing a way to better study a large protein essential for hearing and finding a truncated version of it.

Biologists identify gene involved in kidney-related birth defects

September 18, 2017
A team led by University of Iowa researchers has identified a gene linked to rare, often fatal kidney-related birth defects.

Genomic recycling: Ancestral genes take on new roles

September 18, 2017
One often hears about the multitude of genes we have in common with chimps, birds or other living creatures, but such comparisons are sometimes misleading. The shared percentage usually refers only to genes that encode instructions ...

A new approach to high insulin levels

September 18, 2017
Diabetes is characterised by a deficiency of insulin. Its opposite is a condition called congenital hyperinsulinism—patients produce the hormone too frequently and in excessive quantities, even if they haven't eaten any ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.